No­var­tis backs a $13M round for Anaerophar­ma; Eli Lil­ly in­vest­ing $52M in phar­ma re­search pro­gram with Pur­due

⇨ No­var­tis has joined the syn­di­cate back­ing a $13.1 mil­lion round for Tokyo-based Anaerophar­ma, which is tar­get­ing hy­pox­ic sol­id tu­mors. No­var­tis, Shin­sei Cor­po­rate In­vest­ment Lim­it­ed and Sev­en­ture Part­ners led joined as new in­vestors along­side In­no­va­tion Net­work Cor­po­ra­tion of Japan and Mit­subishi UFJ Cap­i­tal’s man­aged fund.

⇨ Eli Lil­ly is in­vest­ing $52 mil­lion in­to a new re­search pro­gram with Pur­due Uni­ver­si­ty fo­cused on new and bet­ter in­jectable tech and pre­dic­tive mod­els for clin­i­cal suc­cess to help im­prove the odds of win­ning in the clin­ic.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER